Pharmaceutical compositions for combination therapy

Patent metadata

Field	Value
Publication number	US-12337003-B2
Application number	US-202217700317-A
Country	US
Kind code	B2
Filing date	Mar 21, 2022
Priority date	Feb 6, 2015
Publication date	Jun 24, 2025
Grant date	Jun 24, 2025

Abstract

The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one lipid lowering agent (e.g., PPAR-alpha agonist, PPAR-delta agonist, PPAR-alpha and delta dual agonist, and/or statin). Also disclosed is use of the combination for the treatment or prevention of a FXR mediated disease or condition, such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), portal hypertension, bile acid diarrhea, NAFLD (nonalcoholic fatty liver disease), NASH (non-alcohol-induced steatohepatitis), and other chronic liver diseases. The combination of the present invention is useful for the treatment or prevention of conditions related to elevated lipid and liver enzyme levels. The present invention also relates to packs or kits including the pharmaceutical combination.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising a combination of a compound of formula (1):

or a pharmaceutically acceptable salt or amino acid conjugate thereof, and bezafibrate; and optionally one or more pharmaceutically acceptable carriers, wherein bezafibrate is in an amount of 80-400 mg; and
wherein the compound of formula (1) or pharmaceutically acceptable salt or amino acid conjugate thereof is in an amount of about 5 mg or about 10 mg.

2. A pharmaceutical composition comprising a combination of therapeutic agents consisting of a compound of formula (1):

or a pharmaceutically acceptable salt or amino acid conjugate thereof, and bezafibrate; wherein the pharmaceutical composition further optionally comprises one or more pharmaceutically acceptable carriers, wherein bezafibrate is in an amount of 80-400 mg; and
wherein the compound of formula (1) or pharmaceutically acceptable salt or amino acid conjugate thereof is in an amount of about 5 mg or about 10 mg.

3. The pharmaceutical composition of claim 2 , wherein bezafibrate is in an amount of 100-300 mg.

4. The pharmaceutical composition of claim 2 , wherein bezafibrate is in an amount of 100 mg.

5. The pharmaceutical composition of claim 2 , wherein bezafibrate is in an amount of 200 mg.

6. The pharmaceutical composition of claim 2 , wherein bezafibrate is in an amount of 400 mg.

7. The pharmaceutical composition of claim 2 , wherein the composition is a single unit dosage form.

8. The pharmaceutical composition of claim 7 , wherein the single unit dosage form is a tablet or capsule.

9. The pharmaceutical composition of claim 1 , wherein bezafibrate is in an amount of 100-300 mg.

10. The pharmaceutical composition of claim 1 , wherein bezafibrate is in an amount of 100 mg.

11. The pharmaceutical composition of claim 1 , wherein bezafibrate is in an amount of 200 mg.

12. The pharmaceutical composition of claim 1 , wherein bezafibrate is in an amount of 400 mg.

13. The pharmaceutical composition of claim 1 , wherein the composition is a single unit dosage form.

14. The pharmaceutical composition of claim 13 , wherein the single unit dosage form is a tablet or capsule.

15. The pharmaceutical composition of claim 2 , wherein the compound of formula (1) or pharmaceutically acceptable salt or amino acid conjugate thereof is in an amount of about 5 mg and bezafibrate is in an amount of 400 mg.

16. The pharmaceutical composition of claim 15 , wherein the composition is a single unit dosage form.

17. The pharmaceutical composition of claim 16 , wherein the single unit dosage form is a tablet or capsule.

18. The pharmaceutical composition of claim 17 , wherein the single unit dosage form is a tablet.

Assignees

• Intercept Pharmaceuticals Inc

Inventors

• Pruzanski Mark
• Adorini Luciano

Classifications

• A61K31/192

  having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid  {(cannabinoids A61K31/658)} · CPC title

• A61K31/451

  having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine · CPC title

• A61K31/56

  Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/366

  having six-membered rings, e.g. delta-lactones · CPC title